Literature DB >> 24929967

NSAID-gastroenteropathy: new aspects of pathogenesis and prevention.

Rory W Blackler1, Burcu Gemici2, Anna Manko1, John L Wallace3.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) remain among the most commonly used medications because of their effectiveness in reducing pain and inflammation. Inhibitors of gastric acid secretion can substantially reduce the damaging effects of NSAIDs in the stomach and duodenum. However, there are no proven effective preventative or curative treatments for NSAID-induced enteropathy. In recent years, substantial progress has been made in better understanding the pathogenesis of NSAID-enteropathy, and in particular the interplay of enteric bacteria, bile and the enterohepatic recirculation of the NSAIDs. Moreover, it is becoming clear that suppression of gastric acid secretion significantly worsens NSAID-enteropathy.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24929967     DOI： 10.1016/j.coph.2014.05.008

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  20 in total

1.  H2S confers colonoprotection against TNBS-induced colitis by HO-1 upregulation in rats.

Authors:  Krisztina Kupai; Nikoletta Almási; Magdolna Kósa; János Nemcsók; Zsolt Murlasits; Szilvia Török; Amin Al-Awar; Zoltán Baráth; Anikó Pósa; Csaba Varga
Journal:  Inflammopharmacology       Date:  2017-08-02       Impact factor: 4.473

2.  Suppression of contractile activity in the small intestine by indomethacin and omeprazole.

Authors:  Lenard M Lichtenberger; Deepa Bhattarai; Tri M Phan; Elizabeth J Dial; Karen Uray
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-02-26       Impact factor: 4.052

Review 3.  Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter.

Authors:  John L Wallace; Rui Wang
Journal:  Nat Rev Drug Discov       Date:  2015-04-07       Impact factor: 84.694

Review 4.  NSAID enteropathy and bacteria: a complicated relationship.

Authors:  Stephanie D Syer; Rory W Blackler; Rebeca Martin; Giada de Palma; Laura Rossi; Elena Verdu; Premek Bercik; Michael G Surette; Anne Aucouturier; Philippe Langella; John L Wallace
Journal:  J Gastroenterol       Date:  2015-01-10       Impact factor: 7.527

5.  A proof-of-concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide-releasing anti-inflammatory drug.

Authors:  John L Wallace; Peter Nagy; Troy D Feener; Thibault Allain; Tamás Ditrói; David J Vaughan; Marcelo N Muscara; Gilberto de Nucci; Andre G Buret
Journal:  Br J Pharmacol       Date:  2019-04-11       Impact factor: 8.739

6.  Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage.

Authors:  Oscar Sasso; Marco Migliore; Damien Habrant; Andrea Armirotti; Clara Albani; Maria Summa; Guillermo Moreno-Sanz; Rita Scarpelli; Daniele Piomelli
Journal:  FASEB J       Date:  2015-03-10       Impact factor: 5.191

Review 7.  Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition.

Authors:  Carmelo Scarpignato; Ingvar Bjarnason
Journal:  Curr Gastroenterol Rep       Date:  2019-11-13

8.  Exposure to non-steroid anti-inflammatory drugs (NSAIDs) and suppressing hydrogen sulfide synthesis leads to altered structure and impaired function of the oesophagus and oesophagogastric junction.

Authors:  Oksana Zayachkivska; Nazar Bula; Dzvinka Khyrivska; Elena Gavrilyuk; John L Wallace
Journal:  Inflammopharmacology       Date:  2015-02-25       Impact factor: 4.473

9.  Toward More GI-Friendly Anti-Inflammatory Medications.

Authors:  John L Wallace; Gilberto de Nucci; Oksana Sulaieva
Journal:  Curr Treat Options Gastroenterol       Date:  2015-12

Review 10.  Eicosanoids in the gastrointestinal tract.

Authors:  John L Wallace
Journal:  Br J Pharmacol       Date:  2018-04-16       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.